FINHUB Insights

PODD · Q2 FY26 · Apr 1 – Jun 30, 2026

Insulet Q2 FY26: where the revenue came from and where it went

Insulet Q2 FY26: revenue $0.8B (+24% year over year). Net profit $0.10B. Largest cohort U.S. $0.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
May 6, 2026 10-Q
Sankey diagram of Insulet's income statement for Q2 FY26: revenue of $0.80 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$0.80B +24% year over year
Gross profit$0.56B 70% margin
Operating profit$0.13B 16% margin
Net profit$0.10B 12% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 0.80 100% +24%
U.S. 0.52 64% +14%
International 0.24 30% +31%
Other 0.04 5%
Drug delivery <0.01 0%
Cost of revenue−0.2430%
Gross profit0.5670% margin+1pp
R&D−0.0911%+0pp
SG&A−0.3543%+3pp
Operating profit0.1316% margin−2pp
Tax−0.02
Interest & other costs−0.01
Net profit0.1012%+8pp
Filing on EDGAR More quarters of PODD

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.